SCHEMBL3843714

SCHEMBL3843714

CC(C)(C)OC(=O)C1NCCO1

nearest known ligand 0.35

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
MAPK1 P28482 1/20 0.33
GAA P10253 1/20 0.31
RECQL P46063 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28818303 0.88 USP2 (0.31) USP2SMN1; SMN2MAPK1
SCHEMBL28084230 0.79
SCHEMBL5494369 0.78 ARG1 (0.31)
SCHEMBL2134991 0.75 ARG1 (0.38) MAPK1
SCHEMBL2135002 0.75 ARG1 (0.38) MAPK1
SCHEMBL2134995 0.75 ARG1 (0.38) MAPK1
SCHEMBL27435827 0.74 ALDH1A1 (0.35) MAPK1RECQL
SCHEMBL27464952 0.73
SCHEMBL6595404 0.72
SCHEMBL20521203 0.72

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10683257-B2 Methods and intermediates for synthesizing SK1-I ENZO BIOCHEM, INC. (US) 2020-06-16 US disclosed
US-20200131113-A1 METHODS AND INTERMEDIATES FOR SYNTHESIZING SK1-I ENZO BIOCHEM, INC. (US) 2020-04-30 US disclosed
US-20190256453-A1 METHODS AND INTERMEDIATES FOR SYNTHESIZING SK1-I ENZO BIOCHEM, INC. (US) 2019-08-22 US disclosed
US-10364211-B1 Methods and intermediates for synthesizing SK1-I ENZO BIOCHEM, INC. (US) 2019-07-30 US disclosed
CN-108602809-A Inhibitors of isoxazolidine derived receptor interacting protein kinase 1(RIPK 1) 戴纳立制药公司 2018-09-28 CN disclosed
EP-2283150-B1 ASSAY FOR MONITORING ACTIVITY OF JMJD6 ISIS INNOVATION (GB) 2013-01-02 EP disclosed
WO-2009141609-A1 ASSAY FOR MONITORING ACTIVITY OF JMJD6 ISIS INNOVATION LIMITED (GB) 2009-11-26 WO disclosed
CN-1874991-A Compounds capable of binding to the S1P receptor and pharmaceutical uses thereof ONO PHARMACEUTICAL CO (JP) 2006-12-06 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10683257-B2 Methods and intermediates for synthesizing SK1-I SKP1, SKP2, KMT5A USP2 3063/4885SMN1; SMN2 1584/4885MAPK1 247/4885
US-20200131113-A1 METHODS AND INTERMEDIATES FOR SYNTHESIZING SK1-I SKP1, SKP2, KMT5A USP2 3063/4885SMN1; SMN2 1584/4885MAPK1 247/4885
US-20190256453-A1 METHODS AND INTERMEDIATES FOR SYNTHESIZING SK1-I SKP1, SKP2, KMT5A USP2 3063/4885SMN1; SMN2 1584/4885MAPK1 247/4885
US-10364211-B1 Methods and intermediates for synthesizing SK1-I SKP1, SKP2, KMT5A USP2 3063/4885SMN1; SMN2 1584/4885MAPK1 247/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.